.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB20_PegunigalsidaseAlfa.PegunigalsidaseAlfa .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB20_PegunigalsidaseAlfa.PegunigalsidaseAlfa| name: | PegunigalsidaseAlfa | |
| ATC code: | A16AB20 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 0.078 | L/h/kg |
| other parameters in model implementation | ||
Pegunigalsidase alfa is a recombinant human alpha-galactosidase enzyme produced in plant cells, indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare, genetic lysosomal storage disorder. The drug is approved in the EU and Israel, marketed under the name PRX-102.
Pharmacokinetics in adult patients with Fabry disease, both male and female, following intravenous infusion of 1 mg/kg.